The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular
carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently …

The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in
regulating anabolic metabolism. To determine whether PKM2 is required for tumor formation …

Mouse models are the basis of preclinical and translational research in hepatocellular
carcinoma (HCC). Multiple methods exist to induce tumour formation in mice, including …

Approximately 10% to 15% of human cancers lack detectable telomerase activity, and a
subset of these maintain telomere lengths by the telomerase-independent telomere …

Purpose: The aim of our study is to elucidate whether T cells expressing GPC3-targeted
chimeric antigen receptor (CAR) can efficiently eliminate GPC3-positive HCC cells and their …

Cancer immunotherapy has made unprecedented breakthrough in the fields of chimeric
antigen receptor-redirected T (CAR T) cell therapy and immune modulation. Combination of …

Background and Aims Glypican 3 (GPC3) is an oncofetal antigen involved in Wnt-dependent
cell proliferation that is highly expressed in hepatocellular carcinoma (HCC). We …